selected scholarly activity
-
chapters
-
conferences
- The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy. Blood. 9122-9124. 2022
- Natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: a retrospective analysis of the Canadian MDS-CAN registry. Leukemia and Lymphoma. 3165-3174. 2022
- Fitness Assessment of Elderly Patients with AML and Outcomes. Blood. 3379-3379. 2021
- The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes. Blood. 3064-3064. 2021
- Cardiovascular events among recipients of hematopoietic stem cell transplantation. European Heart Journal. ehab724.2876. 2021
- Cardiovascular events among recipients of hematopoietic stem cell transplantation. European Heart Journal. 2876-2876. 2021
- THE IMPACT OF GAINING OR LOSING TRANSFUSION INDEPENDENCE ON QUALITY OF LIFE IN MYELODYSPLASTIC SYNDROMES. Leukemia Research. S25-S26. 2021
- CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study. Blood. 6-7. 2020
- Chronic Lymphocytic Leukemia Treatment in México: Up to Half Patients May Not Requiere Treatment. Blood. 36-37. 2020
- Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study. Blood. 41-43. 2020
- High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS. Blood. 47-48. 2020
- Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. Blood. 35-36. 2020
- Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS. Blood. 1-2. 2020
- AML-303: Systematic Review of Frailty Assessment Tools for Elderly Patients with Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia. S200-S200. 2020
- Patients Who Are Refractory to Ida-FLAG As Initial Induction Chemotherapy for AML Have Persistence of the Dominant Genetic Mutations and a Poor Clinical Outcome. Blood. 2017
- The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules. Blood. 2017
- Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived. Blood. 2800-2800. 2016
- Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7. Blood. 4893-4893. 2015
- Outcomes of Down-Syndrome Associated Acute Lymphoblastic Leukemia in Adults: A Single Center Retrospective Review. Blood. 3717-3717. 2015
- P-116 Frailty is an independent prognostic marker for overall survival in MDS: Results of a Canadian MDS registry. Leukemia Research. S76-S76. 2013
- P-257 The effects of azacitidine on quality of life: A prospective longitudinal assessment. Leukemia Research. S138-S139. 2013
- The Effects of Azacitidine On Quality of Life: A Prospective Longitudinal Assessment. Blood. 4938-4938. 2012
- The Independent Effects of Frailty and Comorbidity On the Quality of Life in MDS Patients. Blood. 699-699. 2012
- Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria. Blood. 1721-1721. 2012
- P500: A REAL WORLD MULTI CENTRE STUDY OF CPX-351 REVEALS NO DIFFERENCE IN OVERALL SURVIVAL WHEN COMPARED WITH FLAG-IDA AND 3 + 7 IN HIGH RISK AML.. HemaSphere. 399-400.
-
journal articles
- Concurrent BCR‐ABL1 and core binding factor beta rearrangement in de novo acute myeloid leukemia: A case report and review of literature. eJHaem. 5:607-615. 2024
- Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia. 38:502-512. 2024
- Ureaplasma-Induced Hyperammonemia Syndrome - an Acute Complication Post Allogeneic Stem Cell Transplant. Blood. 142:6988-6988. 2023
- Analysis of the Impact of Whole Blood and T-Cell Donor Chimerism after Allogeneic Stem Cell Transplant. Blood. 142:2211-2211. 2023
- Concurrent BCR::-ABL1 and CBFB Rearrangement in De Novo Acute Myeloid Leukemia. Blood. 142:5866-5866. 2023
- LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses. Blood. 142:6793-6793. 2023
- LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism. Blood. 142:4156-4156. 2023
- Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies. JACC: CardioOncology. 5:415-430. 2023
- Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis. Bone Marrow Transplantation. 58:478-490. 2023
- Topic: AS02-Epidemiology: EVALUATION OF INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE COHORT STUDY FROM THE CANADIAN MDS REGISTRY. Leukemia Research. 128:107160-107160. 2023
- Topic: AS09-Quality of life-Disease experiences: LONGITUDINAL TRAJECTORY OF QUALITY OF LIFE IN MDS AND IMPACT OF PATIENT-RELATED FACTORS. Leukemia Research. 128:107278-107278. 2023
- Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic Syndromes. JCO Oncology Practice. 19:e559-e569. 2023
- Antiviral therapy defiant mixed viral retinitis post hematopoietic allogeneic stem cell transplant. Clinical Case Reports. 11:e7095. 2023
- The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia and Lymphoma. 64:651-661. 2023
- High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes. Hematology Journal. 108:532-542. 2023
- A Retrospective Cohort Study of Donor Cell Leukemia. Blood. 140:12916-12917. 2022
- The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. Annals of Hematology. 101:1023-1030. 2022
- Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study. British Journal of Haematology. 194:319-324. 2021
- Up to half of patients diagnosed with chronic lymphocytic leukemia in México may not require treatment. Hematology. 25:156-159. 2020
- A case of secondary acute myeloid leukemia on a background of glycogen storage disease with chronic neutropenia treated with granulocyte colony stimulating factor. JIMD Reports. 49:37-42. 2019
- Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Current Opinion in Hematology. 26:16-21. 2019
- AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. Leukemia Research. 68:22-28. 2018
- Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived. Leukemia and Lymphoma. 59:237-240. 2018
- Pseudo-differentiation syndrome. Mediterranean Journal of Hematology and Infectious Diseases. 3:e2011061-e2011061. 2011
- Toxic epidermal necrolysis associated with severe cytomegalovirus infection in a patient on regular hemodialysis. Mediterranean Journal of Hematology and Infectious Diseases. 3:e2011004-e2011004. 2011
-
preprints